The global bacterial vaginosis (BV) drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The rising incidence of bacterial vaginosis among women across the globe coupled with the surging demand for OTC products is augmenting the growth of the market. It is a vaginal disorder that produces vaginal discharge on account of an overgrowth of certain kinds of bacteria in the vagina. BV is a global concern due to the increased risk of the acquisition of sexually transmitted infections. BV can occur in any age group, however, globally it is more prevalent in females of reproductive age. 

According to the American Sexual Health Association 2019, BV is a common gynecologic infection, which affects nearly 29% of women in the US. At least 15% of the sexually active population are suffering from BV; due to this BV is three-four times more common than urinary tract infections (UTI). Hence, the rising incidence of BV is leading to an upsurge in R&D for its treatment by private manufacturers and research organizations. However, several clinical trials are undergoing to enlarge the potential future of bacterial vaginosis drugs. 

Key players of the market include Bayer AG, Pfizer Inc., and Sanofi S.A., among others. The market players are eyeing to strengthen their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on. For instance, in August 2020, Daré Bioscience, Inc., one of the prominent leaders in women’s health innovation, announced the publication of a proof of concept study of DARE-BV1 in Clinical and Experimental Obstetrics & Gynecology, an international journal focused on the publication of high-quality scientific research related to obstetrics and gynaecology and women’s health. DARE-BV1 is a novel thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% that is being evaluated as a one-time vaginally administered treatment for bacterial vaginosis (BV).

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape:  Bayer AG, Pfizer Inc., and Sanofi S.A., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Bacterial Vaginosis Drugs Market by Segmentation

By Type 

• Rx 

• OTC

By Application 

• Hospital

• Pharmacy

• Others

Global Bacterial Vaginosis Drugs Market by Region